INDACATEROL STUDY DATA PRESENTED AT AAAAI
A novel, once-daily beta2-agonist, indacaterol, appears not to cause heart rhythm abnormalities when used to treat patients with persistent asthma, researchers have reported at the 62nd annual meeting of the American Academy of Asthma, Allergy and Immunotherapy (AAAAI).
In the randomized, double-blind, multicenter study, 184 patients aged 13 to 75 years were assigned to either placebo or various doses of indacaterol for management of their asthma. Compared with placebo, the 200 mg, 300 mg, 400 mg and 600 mg daily doses were all superior in improving lung function after the first day of treatment. The differences in forced expiratory volume area under the curve was significantly greater than placebo.